Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313129

— · A

8adc1123-666a-5c45-9c08-89c802e22f58

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • ANGIOGENESIS+0.450
  • ESTROGEN_RESPONSE_EARLY+0.390
  • IL6_JAK_STAT3_SIGNALING+0.370
  • ALLOGRAFT_REJECTION+0.310
  • COAGULATION+0.310
  • INFLAMMATORY_RESPONSE+0.300
  • KRAS_SIGNALING_UP+0.280
  • ESTROGEN_RESPONSE_LATE+0.270
  • INTERFERON_GAMMA_RESPONSE+0.250

Top 10 suppressed

  • E2F_TARGETS-0.680
  • G2M_CHECKPOINT-0.650
  • MYC_TARGETS_V2-0.610
  • MYC_TARGETS_V1-0.560
  • MITOTIC_SPINDLE-0.500
  • MTORC1_SIGNALING-0.380
  • DNA_REPAIR-0.330
  • OXIDATIVE_PHOSPHORYLATION-0.320
  • UNFOLDED_PROTEIN_RESPONSE-0.280
  • PANCREAS_BETA_CELLS-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0308
medullo-epn-umap@date-based
MedMedulloblastoma0.889
2BS_E4F1D721
medullo-epn-umap@date-based
EPNEPN Tumor0.887
3TCGA-A2-A0EN-01A-13R-A084-07
breast-umap@18
—A0.883
4SRR1313130
breast-umap@18
—A0.883
5SRR5088928
melanoma-umap@29
——0.882
6SRR10899975
melanoma-umap@29
——0.881
7c5e09ad2-1f0b-4ea3-9565-a1664f1bb468
melanoma-umap@29
——0.880
8TCGA-55-6980-01A-11R-1949-07
lung-landscapes@6
—cohortA10.879
9BS_ZV9Z3SY6
brain-umap@2
pilocytic astrocytoma—0.877
10MDT-AP-2919
medullo-epn-umap@date-based
MedMedulloblastoma0.875

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
ANGIOGENESIS0.450Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.390Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.370Inavolisib— uncovered
ALLOGRAFT_REJECTION0.310Idelalisib— uncovered
COAGULATION0.310Binimetinib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.280Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.270Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.250Idelalisib— uncovered
COMPLEMENT0.230Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.220Inavolisib— uncovered
APOPTOSIS0.210Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.210Inavolisib— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
BILE_ACID_METABOLISM0.190Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.190Inavolisib— uncovered
IL2_STAT5_SIGNALING0.170Idelalisib— uncovered
MYOGENESIS0.150Inavolisib— uncovered
TGF_BETA_SIGNALING0.150Inavolisib— uncovered